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Purpose: To report the safety and the effectiveness of deep scler-
ectomy (DS) with a new nonabsorbable uveoscleral hema implant
(Esnoper-Clip) designed to increase trabecular and uveoscleral
outflow and to achieve higher intrascleral blebs.
Materials and Methods: Twenty-seven eyes of 27 patients with
open-angle glaucoma, who underwent DS with an Esnoper-Clip
implant, were included in this study. All patients were followed up
after 12 months.
Results: A significant decrease in intraocular pressure was observed
after surgery, changing from a preoperative mean of 26.6±5.2mm
Hg to a postoperative mean of 15.3±5mm Hg (P<0.001) at 12
months. There was also a significant reduction in the number of
glaucoma drugs needed, varying from 2.5 per patient to 0.3
(P<0.001) 1 year after surgery. The main intrascleral lake height
and volume at 12 months was 0.7±0.1mm and 3.9±1.3mm3,
respectively. No intraoperative complications occurred. The main
postoperative complications were a positive Seidel test result at 24
hours in 2 eyes (7.4%), hyphema in 2 eyes (7.4%), and choroidal
detachment in 1 eye (3.7%). All these complications resolved suc-
cessfully. The need for additional mitomycin-C injections was
recorded in 4 eyes (14.8%), twice in 2 of them. Twelve eyes (44.4%)
underwent postsurgical Nd:YAG laser goniopuncture with a mean
time between surgery and this procedure of 4.3 months. Mean
intraocular pressure after Nd:YAG laser goniopuncture decreased
from 19.2 to 15.5mm Hg (P<0.001).
Conclusion: DS with an uveoscleral hema implant (Esnoper-Clip) is
a safe and effective technique for the management of open-angle
glaucoma.
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Glaucoma is a complex eye disease which is the secondcause of blindness in the world. It consists of the
progressive deterioration of the layer of retinal nerve fibers
and of the optic nerve, which lead to the appearance of
defects in the visual field and of atrophy of the optic nerve.
In the majority of cases, this pathology is associated with
increased intraocular pressure (IOP) due to the inhibition of
correct drainage of the aqueous humor of the eye. The
management of glaucoma requires chronic treatment with a
spectrum of therapeutic options including drugs, laser
treatment, incisional filtration surgery, drainage devices,
and surgical implants.
Deep sclerectomy (DS) is a nonpenetrating procedure
for the treatment of open-angle glaucoma (OAG). This can
be enhanced with intraoperative mitomycin-C (MMC) or
with the use of implants designed to avoid secondary col-
lapse by maintaining the space created after removing the
deep scleral flap. These devices can be implanted intra-
sclerally or in the supraciliary space, with a view to facili-
tating trabecular and uveoscleral outflow. Its implantation
in the scleral bed has been more widely practiced, but there
are also a few reports of the placement of the implant in the
supraciliary space1,2 which indicate that it may be a
promising alternative. It is still unknown whether placing
FIGURE 1. The new foldable uveoscleral hema implant (Esnoper-
Clip) designed and developed at the Glaucoma Unit of the
Hospital Universitari Germans Trias i Pujol, Barcelona (Universitat
Autonoma of Barcelona), Spain.
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an implant in the supraciliary space produces a higher
reduction in IOP than in the scleral space, but the main-
tenance of both spaces seems to be related to satisfactory
IOP control. One problem of supraciliary implantation is
that the size of the intrascleral lake could be reduced and
this could lead to less IOP reduction.1 Esnoper-Clip is a
new nonreabsorbable foldable hema implant with 2 ft, one
for the intrascleral bed and the other for the supraciliary
space. Its shape seeks to increase the trabecular and
uveoscleral outflow, maintaining both spaces and achieve
higher intrascleral blebs. The aim of this study was to
evaluate the safety and effectiveness of this implant after a
12-month follow-up and if it could be an alternative to
existing implants.
MATERIALS AND METHODS
The implant used for all patients was the Esnoper-Clip
(AJL Ophthalmics, Álava, Spain), a new uveoscleral hema
implant developed at the Glaucoma Unit of the Hospital
Universitari Germans Trias i Pujol, Barcelona (Universitat
Autonoma of Barcelona, Spain). It is a nonreabsorbable
and foldable hema implant (2-hydroxyethyl methacrylate)
with 2 ft designed to maintain supraciliary and intrascleral
spaces and to achieve higher intrascleral blebs (Fig. 1).
Patients
This study, to evaluate the safety and effectiveness of
Esnoper-Clip implants, involved a prospective analysis of
27 eyes from 27 patients with OAG who underwent DS
with an uveoscleral implant (Esnoper-Clip) implant
between October 2011 and January 2013 followed up 1 year
after surgery. Their surgical history included 16 uneventful
phacoemulsifications, performed at least 6 months before
surgery. All patients were over 18 years of age and pre-
sented with uncontrollable primary or secondary OAG IOP
(Z21mm Hg), or were under maximal tolerable medical
treatment. They signed the consent form approved by the
Department of Ophthalmology of the Hospital Germans
Trias i Pujol (Barcelona, Spain) and the study was con-
ducted in accordance with the principles established in the
Declaration of Helsinki and was approved by the Institu-
tional Review Board of the Hospital Germans Trias I Pujol
(Barcelona, Spain). Exclusion criteria were prior
FIGURE 2. Surgical technique. A, Superficial scleral flap (55 mm2) of one third of the scleral depth, reaching 2 mm of clear cornea. B,
Deep 44 mm2 scleral flap is dissected and removed, and Schlemm canal was deroofed with a capsulorhexis forceps. The implant has 2
plates; one was placed in a full-thickness suprachoroidal bag 2 mm behind the scleral spur. C, After folding the implant the other foot
was placed into the intrascleral lake. It can be fixed without suturing because it has 2 lateral notches that do not allow anterior
displacement. D, To achieve higher intrascleral blebs, an intrascleral pocket was created at the posterior limit of the intrascleral bed to fix
the posterior edge of the implant, thereby helping to keep the scleral lips apart.
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antiglaucoma surgery, or any other surgery which could
have affected the conjunctiva in the region of the inter-
vention, including cataract surgery 6 months before the
present intervention, moderate or severe diabetic retinop-
athy, and other causes of ocular neovascularization. We
also excluded glaucoma patients with a high risk of failure,
that is those presenting with neovascularization, aphakia,
inflammation, juvenile cases, and cases of posttrauma and
postsurgery glaucoma.
In the preoperative assessment, patients underwent a
complete examination including best-corrected visual acuity
(BCVA) on a decimal scale, biomicroscopy, Goldmann
tonometry, pachymetry (UP-1000; Nidek, Japan) gonio-
scopy, fundoscopy, and the glaucoma therapy was recorded.
Follow-up visits were scheduled at 24 hours, 1, 3, 6,
and 12 months after surgery, and included BCVA, slit-lamp
examination, tonometry, gonioscopy, and fundoscopy.
Anterior segment optical coherence tomography (AS-OCT)
(Visante OCT; Carl Zeiss Meditec, Jena, Germany) which
provides an objective method to assess the anterior segment
of the eye and the surgical area, was performed at months 1,
3, 6, and 12, to the intrascleral bleb height at 90 and 180
degrees and the highest was chosen. To determinate the
volume of the intrascleral lake, the semiellipsoid has been
considered to be the most similar geometric shape. We
calculated its value from the height (H), the vertical dia-
meter or length (L), and the horizontal diameter or width
(W) using the formula Volume=1/6pHLW. AS-
OCT measurements and analysis were performed by the
same investigator (J.C.M.).
Surgical Technique
All surgical operations were performed by the same
surgeon (J.L.A.). A superior 4/0 nylon traction suture was
passed through the superior cornea and a fornix-based
conjunctival flap was dissected (Fig. 2A), followed by
cauterization of bleeding vessels and dissection of the
superficial scleral flap (55mm2) of one third of the scleral
depth, extending 2mm into clear cornea. Afterwards, a
MMC impregnated sheet was laid between the scleral flap
and the remaining sclera as well as over the flap, and left
there for 2 minutes and then irrigated thoroughly with
balanced salt solution. Subsequently, a deeper 44mm2
scleral flap was dissected and removed, and Schlemm canal
was deroofed with a capsulorhexis forceps. The implant has
2 plates; 1 was placed in a full-thickness suprachoroidal bag
2mm behind the scleral spur, after the technique firstly
described by Muñoz1 (Fig. 2B). After folding the implant
the other foot was placed into the intrascleral lake
(Fig. 2C). It can be fixed without suturing because it has 2
lateral notches that do not allow anterior displacement. To
achieve higher intrascleral blebs, an intrascleral pocket was
created at the posterior limit of the intrascleral bed to fix
the posterior edge of the implant, thereby helping to keep
the scleral lips apart (Fig. 2D). No suture or a loose one,
was used for the superficial scleral flap and the conjunctiva
was sutured with a nylon 10/0. Postoperative treatment
consisted of topical ofloxacin (Exocin; Alcon Cusı́ SA, El
Masnou, Barcelona, Spain) 4 times a day during 1 week and
prednisolone acetate (10mg/mL) (Predforte; Allergan
Pharmaceuticals Ireland, Westport, Ireland) 6 times a day,
the latter in a descending dosage over 6 weeks. Gonio-
puncture with the YAG laser (Visulas YAG III Combi;
Carl Zeiss Meditec, Dublin, CA) was performed when
percolation of aqueous humor was considered insufficient.
Statistical Analysis
Statistical analyses were performed using SPSS soft-
ware for Windows (version 15.0; SPSS Inc., Chicago, IL).
All data were reported as means with SD. The differences in
continuous variables before and after surgery were com-
pared statistically using the nonparametric Friedman test.
Differences in presurgery IOP values and those measured at
each follow-up were analyzed using the Wilcoxon matched-
pairs signed-rank test. Probability values <0.05 were con-
sidered to be statistically significant.
RESULTS
Demographics and characteristics of patients included
in this study are shown in Table 1. Mean preoperative IOP
was 26.6±5.2mm Hg. Twelve months later, we found a
statistically significant reduction in IOP which had reached a
mean of 15.3±5mm Hg (P<0.001). This change repre-
sents a 42.5% reduction in IOP reduction (Table 2). There
was also a statistically significant reduction in the number of
medications after surgery, starting with a mean of 2.5 and
arriving at 0.3 at the end of the study (P<0.001) (Fig. 3).
The most common type of glaucoma that was included in the
study was primary open-angle glaucoma (88.9% of patients).
The mean volume and height of the intrascleral bleb 12
months after surgery were 3.9±1.3mm3 and 0.7±0.1mm,
respectively (Fig. 3).
No intraoperative complications occurred. The main
postoperative complications were Seidel at 24 hours in 2
eyes (7.4%), hyphema in 2 eyes (7.4%), choroidal detach-
ment in 1 eye (3.7%), all of which resolved successfully and
the need for additional MMC injections in 4 eyes (14.8%)
(in 2 eyes, on 2 occasions). No statistically significant var-
iation was found between preoperative and postoperative
BCVA (P=0.507). Twelve eyes (44.4%) underwent post-
surgical Nd:YAG goniopuncture (Nd:YAG GP) with a
mean time between surgery and this procedure of 4.3
TABLE 1. Clinical and Demographic Characteristics of Patients








Phakic [n (%)] 11 (40.76)
Pseudophakic [n (%)] 16 (59.24)














BCVA indicates best-corrected visual acuity; IOP, intraocular pressure;
NTG, normal tension glaucoma; POAG, primary open-angle glaucoma;
PSXG, pseudoexfoliative glaucoma.
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months. Complications related to goniopuncture were
limited to choroidal detachment in 1 eye that resolved
uneventfully. In this case, IOP dropped from 20 to 2mm
Hg. The mean IOP after Nd:YAG GP decreased from 19.2
to 15.5mm Hg (P<0.001).
DISCUSSION
DS with a supraciliary implant is an alternative that
has been shown to be safe and effective with different types
of implants.1,2 The main problem with this class of implants
is that they are not specifically designed for this space, and
so their effectiveness can be limited. The intrascleral lake
can lose height or even collapse over time and probably lose
efficacy, because intrascleral bleb height plays an important
role in lowering IOP.3–5 In contrast, intrascleral implants
do not facilitate uveoscleral outflow as well as supraciliary
implants.
Reports of supraciliary implantation are somewhat
scarce and until now no studies with ultrasound bio-
microscopy (UBM) or AS-OCT have been published.
Muñoz1 reported isolated DS and Bonilla et al2 described
phaco-DS resulting in IOP reductions from 26.4±6.9 to
14±3.3mm Hg and 23±5 to 18±3mm Hg, respectively,
after 1 year. In these series, the number of medications was
reduced from 2.8 to 0.3 and from 2.5 to 0.7, respectively. In
our series, IOP decreased from 26.6 to 15.3mm Hg and the
number of drugs to be taken was reduced from 2.5 to 0.26
at 12 months. The incidence of complications is similar to
that associated with intrascleral or supraciliary implanta-
tion described by other authors. We can conclude that the
present technique has no more additional complications for
DS than other alternatives.
The importance and significance of the intrascleral and
suprachoroidal spaces is a controversial issue, but currently
it is widely accepted that both are good prognostic factors,
but not the ones. This controversy may be due to discrep-
ancies in findings using AS-OCT or UBM. UBM meas-
urements have limited resolution and with AS-OCT, it is
very difficult to determine the presence or absence of
uveoscleral outflow.
Mavrakanas et al3 and Fernandez-Buenaga et al4 using
AS-OCT, Perez-Rico without impant and Marchini et al5
using UBM reported a positive inverse correlation between
postoperative IOP and intrascleral bleb height. Mavrakanas
et al3 only investigated eyes having DS with a collagen implant
and postoperatively clinically flat blebs, whereas Fernández-
Buenaga et al4 investigated a heterogeneous group of eyes after
DS using 3 different implants (Aquaflow, Esnoper, SK-Gel).
Both authors found bleb heights between 0.58 and 0.65mm,
respectively, and found a significant correlation between height
and IOP with Esnoper and Aquaflow implants. Here, we have
not studied the correlation between IOP and intrascleral vol-
ume or height, but we did calculate the mean median bleb
height (0.78±0.1mm) and volume (3.9±1.3mm3) 12
months after operation. These values in volume (P=0.706) or
height (P=0.586) were not significantly different to those
before operation.
Another point to be considered is that the shape of our
implant tries to keep the sclera lips apart, thereby facili-
tating transcleral outflow (Fig. 4). This could decrease the
height and volume of the intrascleral lake but in contrast,
transcleral outflow represents a link between the intrascleral
lake and the conjunctival filtering blebs and it had been
found withUBM6 to be a positive prognostic factor. Perez-
Rico et al5 using AS-OCT reported transcleral outflow to
be a positive factor in 89.4% of eyes, 5 years after DS
TABLE 2. Intraocular Pressure Evolution and Numbers of Medications
Preoperative 24H 1Mo 3Mo 6Mo 12Mo
Intraocular pressure (mm Hg±SD) 26.6±5.2 7.3±8.1 14.2±6.5 12.7±4.5 15.3±4.6 15.3±5.0
No. drugs (n±SD) 2.52±0.89 0±0 0±0 0±0 0.16±0.62 0.26±0.69
Goniopuncture (%) — 0 3.7 18.5 25.9 44.4
FIGURE 3. A, Mean changes in intraocular pressure (IOP) and number of medications (treatment). B, Mean changes in volume and
height of the intrascleral lake.
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without implant. This finding brings into question the
mandatory use of implants in DS. The same author
reported the association between lower IOP and maximum
anteroposterior length, height, and intrascleral volume.
It had been published, in studies with UBM, as the
tissue heals with scarring occupying the intrascleral lake6
over time in almost 10% of eyes with7 or without implants.8
Using AS-OCT in eyes which have undergone DS without
implant, the presence of the intrascleral lake had been
revealed in 100% of the eyes after 5 years.5 Discrepancies in
these results are probably related to the trabeculo-Descemet
membrane (TDM) thickness and to the fact that if there is
insufficient peeling of the inner wall of Schlemm canal,
enough outflow will not be achieved to maintain the
intrascleral lake.
Uveoscleral outflow in different series has a prevalence
from 7% to 60%.9,10 However, these series are hardly
comparable because they used different implants with
varying follow-up times. Using UBM7,11 it has been found
that eyes with suprachoroidal filtration have lower IOP
than those without suprachoroidal filtration, whereas other
authors8 could find no evidence of suprachoroidal filtration
in any case, 1 year after surgery. Ravinet et al12 also found
a similar rate of IOP and postoperative treatments in eyes
with or without hypoechoic areas after DS with T-Flux and
Healon GV. Supraciliary implantation probably favors
either a ciliary body detachment with subsequent decrease
in aqueous production, or choroidal resorption leading to
low postoperative IOP. Although it seems logical to think
that this could encourage late chronic ocular hypotony,
there is no evidence of this in the literature or in the present
series. Nevertheless, it should not be forgotten that young
myopics are probably more likely to suffer from hypotony
with supraciliary implantation.
The reported incidence of goniopuncture varies dras-
tically from 4.7% to 63%. This wide variation is likely due
to the application of different criteria, implants, and IOP
targets. The type of implant is likely a very significant factor
in Nd:YAG GP as some implants may enhance more fib-
rosis over the TDM, or displacement above the TDM. This
new device which we report here has 2 lateral notches that
prevent this from happening, and even in cases in which it
does not remain fixed in the suprachoroidal bag, its shape
does not collapse the TDM which remains always free
without any filtration limitations.
On the basis of the present findings, the uveoscleral
implant (Esnoper-Clip) can be considered to be a promising
alternative because it ensures the maintenance of both
spaces helping to avoid collapse over time. Further clinical
trials with long-term follow-up and a larger numbers of
patients will be needed to assess the effectiveness of this new
uveoscleral implant, the morphology of the surgical area,
the real relevance of the intrascleral lake characteristics,
and their correlation with reduced IOP.
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